Article
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Rating:
0.0
Views:
86
Likes:
1
Library:
1
Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value